Literature DB >> 25979753

EGFR and NF-κB: partners in cancer.

Kateryna Shostak1, Alain Chariot2.   

Abstract

Oncogenic proteins cooperate to promote tumor development and progression by sustaining cell proliferation, survival and invasiveness. Constitutive epidermal growth factor receptor (EGFR) and nuclear factor κb (NF-κB) activities are seen in multiple solid tumors and combine to provide oncogenic signals to cancer cells. Understanding how these oncogenic pathways are connected is crucial, given their role in intrinsic or acquired resistance to targeted anticancer therapies. We review molecular mechanisms by which both EGFR- and NF-κB-dependent pathways establish positive loops to increase their oncogenic potential. We also describe how NF-κB promotes resistance to EGFR inhibitors.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  EGFR; NF-κB; erlotinib; gefitinib; resistance; tumor-initiating cells

Mesh:

Substances:

Year:  2015        PMID: 25979753     DOI: 10.1016/j.molmed.2015.04.001

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  84 in total

1.  CD317 Activates EGFR by Regulating Its Association with Lipid Rafts.

Authors:  Guizhong Zhang; Xin Li; Qian Chen; Junxin Li; Qingguo Ruan; Youhai H Chen; Xiaolu Yang; Xiaochun Wan
Journal:  Cancer Res       Date:  2019-03-19       Impact factor: 12.701

2.  Suppression of migration, invasion, and metastasis of cisplatin-resistant head and neck squamous cell carcinoma through IKKβ inhibition.

Authors:  Jipei Liao; Zejia Yang; Brandon Carter-Cooper; Elizabeth T Chang; Eun Yong Choi; Bhaskar Kallakury; Xuefeng Liu; Rena G Lapidus; Kevin J Cullen; Hancai Dan
Journal:  Clin Exp Metastasis       Date:  2020-02-04       Impact factor: 5.150

Review 3.  The role of deubiquitinases in breast cancer.

Authors:  Zhenna Xiao; Peijing Zhang; Li Ma
Journal:  Cancer Metastasis Rev       Date:  2016-12       Impact factor: 9.264

4.  Quantification of growth factor signaling and pathway cross talk by live-cell imaging.

Authors:  Sean M Gross; Peter Rotwein
Journal:  Am J Physiol Cell Physiol       Date:  2017-01-18       Impact factor: 4.249

5.  Antitumor activity of high-dose pulsatile gefitinib in non-small-cell lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.

Authors:  Yitao Wan; Yuan Yuan; Yueyin Pan; Ying Zhang
Journal:  Exp Ther Med       Date:  2017-04-18       Impact factor: 2.447

6.  Metalloprotease-dependent activation of EGFR modulates CD44+/CD24- populations in triple negative breast cancer cells through the MEK/ERK pathway.

Authors:  Randi Wise; Anna Zolkiewska
Journal:  Breast Cancer Res Treat       Date:  2017-08-08       Impact factor: 4.872

7.  Complex Rab4-Mediated Regulation of Endosomal Size and EGFR Activation.

Authors:  Kate Tubbesing; Jamie Ward; Raymond Abini-Agbomson; Aditi Malhotra; Alena Rudkouskaya; Janine Warren; John Lamar; Nina Martino; Alejandro P Adam; Margarida Barroso
Journal:  Mol Cancer Res       Date:  2020-02-04       Impact factor: 5.852

8.  NF-κB-driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance.

Authors:  Ching-Feng Chiu; Yi-Wen Chang; Kuang-Tai Kuo; Yu-Shiuan Shen; Chien-Ying Liu; Yang-Hao Yu; Ching-Chia Cheng; Kang-Yun Lee; Feng-Chi Chen; Min-Kung Hsu; Tsang-Chih Kuo; Jui-Ti Ma; Jen-Liang Su
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-18       Impact factor: 11.205

9.  Investigation of major genetic alterations in neuroblastoma.

Authors:  Régis Afonso Costa; Héctor N Seuánez
Journal:  Mol Biol Rep       Date:  2018-02-17       Impact factor: 2.316

10.  Functional Genomics Approach Identifies Novel Signaling Regulators of TGFα Ectodomain Shedding.

Authors:  Jennifer L Wilson; Eirini Kefaloyianni; Lauren Stopfer; Christina Harrison; Venkata S Sabbisetti; Ernest Fraenkel; Douglas A Lauffenburger; Andreas Herrlich
Journal:  Mol Cancer Res       Date:  2017-10-10       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.